Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant degs » significant genes (Expand Search), significant adverse (Expand Search), significant cause (Expand Search)
degs increases » ses increases (Expand Search), drugs increased (Expand Search), loss increases (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant degs » significant genes (Expand Search), significant adverse (Expand Search), significant cause (Expand Search)
degs increases » ses increases (Expand Search), drugs increased (Expand Search), loss increases (Expand Search)
-
1961
-
1962
The characteristics of patient groups were used to prove the method’s applicability.
Published 2025Subjects: -
1963
-
1964
-
1965
-
1966
ROS, K<sup>+</sup> efflux and cathepsin B are required for NLRP3 activation.
Published 2025Subjects: -
1967
-
1968
-
1969
Differences in health-related quality of life indexes after disease onset between groups.
Published 2025Subjects: -
1970
Changes in subcutaneous fat thickness and muscle mass (Approximately here).
Published 2025Subjects: -
1971
-
1972
-
1973
Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment.
Published 2025Subjects: -
1974
-
1975
-
1976
-
1977
-
1978
-
1979
-
1980